Gotham Asset Management Boosts Biogen Stake by 65%

Institutional investor now owns over 270,000 shares of the biotech company.

Mar. 16, 2026 at 10:39am

Got story updates? Submit your updates here. ›

Gotham Asset Management LLC increased its holdings in Biogen Inc. (NASDAQ:BIIB) by 65.5% in the third quarter, according to the company's recent SEC filing. The institutional investor now owns 270,498 shares of the biotechnology company's stock, valued at approximately $37.89 million.

Why it matters

Biogen is a major player in the biotechnology industry, known for its treatments for multiple sclerosis and other neurological conditions. Institutional investors like Gotham Asset Management closely monitor and adjust their positions in companies like Biogen, which can signal broader market trends and investor sentiment.

The details

Gotham Asset Management acquired an additional 107,009 shares of Biogen during the third quarter, bringing its total stake to 270,498 shares. This represents approximately 0.18% of Biogen's outstanding stock. The increased investment comes as Biogen's stock price has fluctuated in recent months, opening up potential opportunities for savvy investors.

  • Gotham Asset Management increased its Biogen holdings in the third quarter of 2026.
  • Biogen's stock price has seen volatility in recent months.

The players

Gotham Asset Management LLC

An institutional investment firm that manages a portfolio of stocks, including a significant position in Biogen.

Biogen Inc.

A multinational biotechnology company focused on developing and delivering therapies for neurological and neurodegenerative diseases.

Got photos? Submit your photos here. ›

The takeaway

Gotham Asset Management's increased stake in Biogen reflects the continued interest and investment in the biotech industry, particularly in companies with a strong pipeline of neurological treatments. This move highlights the importance of closely monitoring institutional investor activity in the market.